Literature DB >> 7981584

A comparative study on antibodies to nucleoli and 5-hydroxytryptamine in patients with fibromyalgia syndrome and tryptophan-induced eosinophilia-myalgia syndrome.

R Klein1, P A Berg.   

Abstract

Eosinophilia myalgia syndrome (EMS) has been related to intake of "contaminated" L-tryptophan, and an alteration in tryptophan 5-hydroxytryptamine (5-HT, serotonin) metabolism has been reported in EMS patients. Recently we found that a defined autoantibody pattern consisting of antibodies to nucleoli, gangliosides, and phospholipids is closely related to the fibromyalgia syndrome (FS) which clinically resembles the EMS. We were therefore interested to see whether these antibodies can also be detected in patients with EMS. Studied were 27 patients with acute EMS (13 of whom were also examined 2 years after acute onset), 100 patients with FS, and 40 patients with progressive systemic sclerosis (PSS). As controls, sera from 100 blood donors were analyzed. Antibodies to nucleoli were demonstrated by immunofluorescence test on cell cultures in 52% of patients with acute EMS, 62% of patients with chronic EMS, and 37% of FS patients. Western blotting with a nuclear extract from HeLa cells revealed in both diseases the same epitopes at 63, 57, and 53 kDa. Antibodies to 5-HT, gangliosides (Gm1), and phospholipids were determined by enzyme-linked immunosorbent assay. Among patients with FS 73% had antibodies to 5-HT, in contrast to only 19% of patients with acute EMS. However, 77% of the 13 EMS patients analyzed 2 years later had become anti-5-HT antibody positive during that time. Also the incidence of antibodies to Gm1 increased from 37% at acute onset to 69% in patients with chronic EMS (30%). The various antibodies were detected in only 18% of healthy controls.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7981584     DOI: 10.1007/BF00207485

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  42 in total

1.  Dermal fibrosis following subcutaneous injections of serotonin creatinine sulphate.

Authors:  R A MACDONALD; S L ROBBINS; G K MALLORY
Journal:  Proc Soc Exp Biol Med       Date:  1958-02

2.  Musculosketal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects.

Authors:  H Moldofsky; P Scarisbrick; R England; H Smythe
Journal:  Psychosom Med       Date:  1975 Jul-Aug       Impact factor: 4.312

3.  Interim guidance on the eosinophilia-myalgia syndrome.

Authors:  E M Kilbourne; L A Swygert; R M Philen; R K Sun; S B Auerbach; L Miller; D E Nelson; H Falk
Journal:  Ann Intern Med       Date:  1990-01-15       Impact factor: 25.391

4.  Clinical follow-up and immunogenetic studies of 32 patients with eosinophilia-myalgia syndrome.

Authors:  L D Kaufman; B L Gruber; P K Gregersen
Journal:  Lancet       Date:  1991-05-04       Impact factor: 79.321

5.  Tryptophan metabolism. A hitherto unreported abnormality occurring in a family.

Authors:  J M Price; N Yess; R R Brown; A M Johnson
Journal:  Arch Dermatol       Date:  1967-05

6.  5-Hydroxytryptamine and tryptamine pathways in scleroderma.

Authors:  A Stachow; S Jablonska; A Skiendzielewska
Journal:  Br J Dermatol       Date:  1977-08       Impact factor: 9.302

7.  Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis.

Authors:  Y Okano; T A Medsger
Journal:  Arthritis Rheum       Date:  1990-12

8.  Anti-NOR 90. A new autoantibody in scleroderma that recognizes a 90-kDa component of the nucleolus-organizing region of chromatin.

Authors:  J L Rodriguez-Sanchez; C Gelpi; C Juarez; J A Hardin
Journal:  J Immunol       Date:  1987-10-15       Impact factor: 5.422

9.  Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome.

Authors:  R Klein; M Bänsch; P A Berg
Journal:  Psychoneuroendocrinology       Date:  1992-11       Impact factor: 4.905

10.  An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use.

Authors:  E A Belongia; C W Hedberg; G J Gleich; K E White; A N Mayeno; D A Loegering; S L Dunnette; P L Pirie; K L MacDonald; M T Osterholm
Journal:  N Engl J Med       Date:  1990-08-09       Impact factor: 91.245

View more
  4 in total

1.  L-tryptophan contaminant 'peak E' induces the release of IL-5 and IL-10 by peripheral blood mononuclear cells from patients with functional somatic syndromes.

Authors:  H Barth; R Klein; P A Berg
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

Review 2.  Melatonin therapy in fibromyalgia.

Authors:  Russel J Reiter; Dario Acuna-Castroviejo; Dun-xian Tan
Journal:  Curr Pain Headache Rep       Date:  2007-10

3.  A randomised double-blind 16-week study of ritanserin in fibromyalgia syndrome: clinical outcome and analysis of autoantibodies to serotonin, gangliosides and phospholipids.

Authors:  R Olin; R Klein; P A Berg
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

4.  Is there a predisposition for the development of autoimmune diseases in patients with fibromyalgia? Retrospective analysis with long term follow-up.

Authors:  Ina Kötter; Daniela Neuscheler; Ilhan Günaydin; Dorothee Wernet; Reinhild Klein
Journal:  Rheumatol Int       Date:  2007-07-20       Impact factor: 2.631

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.